联合PHI密度、MRI与既往阴性活检状态提高临床显著前列腺癌检出
本研究纳入241例无前列腺癌既往诊断、PSA升高且直肠指检正常、活检前前瞻性行PHI检测的男性,回顾性计算PHI密度(PHID)。91例(37.8%)活检证实为临床显著前列腺癌,PHID对其鉴别能力优于PHI及其他PSA衍生物,联合年龄、既往阴性活检状态及PI-RADS评分后诊断性能进一步提升。
要点
- PHID对临床显著前列腺癌的鉴别能力优于PHI及其他PSA衍生物。
- 联合年龄、既往阴性活检状态与PI-RADS评分可进一步提升PHID诊断性能。
- 以0.44为PHID阈值可避免35.3%的不必要活检,代价是漏诊7.7%的临床显著癌。
核心结论
- 在因诊断前列腺癌接受前列腺活检的当代男性队列中,PHID在临床显著癌诊断上优于PHI及其他PSA衍生物。
- 纳入年龄、既往阴性活检状态和PI-RADS评分后,PHID的诊断性能进一步提升。
- PI-RADS评分与PHID具有互补性。
- 尽管结果令人鼓舞,仍需前瞻性验证。
研究设计与样本
- 研究纳入无前列腺癌既往诊断、PSA升高且直肠指检正常、活检前前瞻性行PHI检测的男性,共241例符合条件。
- PHID采用活检时经直肠超声测得的前列腺体积回顾性计算。
- 采用单变量与多变量logistic回归及ROC曲线分析评估血清标志物预测活检临床显著前列腺癌的能力。
- 临床显著前列腺癌定义为GG≥2,或GG1且>2针阳性或任一针>50%受累。
- 回归模型纳入年龄、既往阴性活检状态和PI-RADS评分。
主要发现
- 241例中91例(37.8%)活检为临床显著前列腺癌。
- PHID中位数(四分位距)为0.74(0.44-1.24);活检有临床显著癌者为1.18(0.77-1.83),无者为0.55(0.38-0.89)(P < 0.001)。
- 单变量logistic回归中,年龄和既往阴性活检状态与临床显著癌相关。
- 在所测标志物中,PHID对临床显著病的鉴别能力最高(单变量模型AUC 0.78),纳入年龄和既往阴性活检状态的多变量模型AUC为0.82。
- 104例接受MRI者中,PI-RADS评分与PHID互补,PI-RADS评分≥3或PI-RADS评分≤2时PHID≥0.44可检出100%的临床显著病;该亚组多变量logistic回归(纳入年龄、既往阴性活检状态和PI-RADS评分)中PHID的AUC为0.90。
关键数值与推荐
- 临床显著前列腺癌定义:GG≥2,或GG1且>2针阳性或任一针>50%受累。
- PHID阈值0.44为队列PHID第25百分位数,对临床显著前列腺癌敏感性92.3%、特异性35.3%。
- PHID对GG≥2的敏感性93.0%、特异性32.4%;对GG≥3的敏感性97.4%、特异性29.1%。
- PI-RADS评分≥3,或PI-RADS评分≤2时PHID≥0.44,可检出100%的临床显著病(104例接受MRI者中)。
临床怎么用
- 对于PSA升高、直肠指检正常且无前列腺癌既往诊断、拟行活检的男性,可考虑检测PHI并计算PHID以辅助判断临床显著前列腺癌风险。
- 结合年龄、既往阴性活检状态和PI-RADS评分可进一步提升PHID的诊断性能。
- 以0.44为PHID阈值时,可在漏诊7.7%临床显著癌的代价下避免35.3%的不必要活检。
- 上述结果尚需前瞻性验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the performance of Prostate Health Index (PHI) density (PHID) combined with MRI and prior negative biopsy (PNB) status for the diagnosis of clinically significant prostate cancer (PCa). PATIENTS AND METHODS: Patients without a prior diagnosis of PCa, with elevated prostate-specific antigen and a normal digital rectal examination who underwent PHI testing prospectively prior to prostate biopsy were included in this study. PHID was calculated retrospectively using prostate volume derived from transrectal ultrasonography at biopsy. Univariable and multivariable logistic regression modelling, along with receiver-operating characteristic (ROC) curve analysis, was used to determine the ability of serum biomarkers to predict clinically significant PCa (defined as either grade group [GG] ≥2 disease or GG1 PCa detected in >2 cores or >50% of any one core) on biopsy. Age, PNB status and Prostate Imaging Reporting and Data System (PI-RADS) score were incorporated into the regression models. RESULTS: Of the 241 men who qualified for the study, 91 (37.8%) had clinically significant PCa on biopsy. The median (interquartile range) PHID was 0.74 (0.44-1.24); it was 1.18 (0.77-1.83) and 0.55 (0.38-0.89) in those with and without clinically significant PCa on biopsy, respectively (P < 0.001). On univariable logistic regression, age and PNB status were associated with clinically significant cancer. Of the tested biomarkers, PHID demonstrated the highest discriminative ability for clinically significant disease (area under the ROC curve [AUC] 0.78 for the univariable model). That continued to be the case in multivariable logistic regression models incorporating age and PNB status (AUC 0.82). At a threshold of 0.44, representing the 25th percentile of PHID in the cohort, PHID was 92.3% sensitive and 35.3% specific for clinically significant PCa; the sensitivity and specificity were 93.0% and 32.4% and 97.4% and 29.1% for GG ≥2 and GG ≥3 disease, respectively. In the 104 men who underwent MRI, PI-RADS score was complementary to PHID, with a PI-RADS score ≥3 or, if PI-RADS score ≤2, a PHID ≥0.44, detecting 100% of clinically significant disease. For that subgroup, of the biomarkers tested, PHID (AUC 0.90) demonstrated the highest discriminative ability for clinically significant disease on multivariable logistic regression incorporating age, PNB status and PI-RADS score. CONCLUSIONS: In this contemporary cohort of men undergoing prostate biopsy for the diagnosis of PCa, PHID outperformed PHI and other PSA derivatives in the diagnosis of clinically significant cancer. Incorporating age, PNB status and PI-RADS score led to even further gains in the diagnostic performance of PHID. Furthermore, PI-RADS score was found to be complementary to PHID. Using 0.44 as a threshold for PHID, 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically significant cancers. Despite these encouraging results, prospective validation is needed.
引用
- Druskin SC, Tosoian JJ, Young A, et al. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int. 2018. PMID: 29232037. doi:10.1111/bju.14098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。